Abstract
According to the newest World Health Organization (WHO) classification for soft tissue tumors in 2013, malignant fibrous histiocytoma (MFH) has been gone. Most sarcomas called MFH were reclassified to be high-grade pleomorphic forms of leiomyosarcoma, liposarcoma, rhabdomyosarcoma, and other sarcomas by recent molecular technologies. However, about 10% to 15% of sarcomas called MFH before, still cannot be given a precise classification, and these are now called undifferentiated pleomorphic sarcoma or are still called MFH. Further molecular approaches including proteomic approaches are imperative to classify these unclassified sarcomas for improving clinical outcomes of the patients with soft tissue sarcomas. This article is part of a Special Issue entitled: Medical Proteomics.
| Original language | English |
|---|---|
| Pages (from-to) | 696-701 |
| Number of pages | 6 |
| Journal | Biochimica et Biophysica Acta - Proteins and Proteomics |
| Volume | 1854 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2015 Jun 1 |
Fingerprint
Keywords
- Classification
- MFH
- Proteomics
- STS
ASJC Scopus subject areas
- Biochemistry
- Biophysics
- Analytical Chemistry
- Molecular Biology
Cite this
Global protein-expression profiling for reclassification of malignant fibrous histiocytoma. / Kikuta, Kazutaka; Morioka, Hideo; Kawai, Akira; Kondo, Tadashi.
In: Biochimica et Biophysica Acta - Proteins and Proteomics, Vol. 1854, No. 6, 01.06.2015, p. 696-701.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Global protein-expression profiling for reclassification of malignant fibrous histiocytoma
AU - Kikuta, Kazutaka
AU - Morioka, Hideo
AU - Kawai, Akira
AU - Kondo, Tadashi
PY - 2015/6/1
Y1 - 2015/6/1
N2 - According to the newest World Health Organization (WHO) classification for soft tissue tumors in 2013, malignant fibrous histiocytoma (MFH) has been gone. Most sarcomas called MFH were reclassified to be high-grade pleomorphic forms of leiomyosarcoma, liposarcoma, rhabdomyosarcoma, and other sarcomas by recent molecular technologies. However, about 10% to 15% of sarcomas called MFH before, still cannot be given a precise classification, and these are now called undifferentiated pleomorphic sarcoma or are still called MFH. Further molecular approaches including proteomic approaches are imperative to classify these unclassified sarcomas for improving clinical outcomes of the patients with soft tissue sarcomas. This article is part of a Special Issue entitled: Medical Proteomics.
AB - According to the newest World Health Organization (WHO) classification for soft tissue tumors in 2013, malignant fibrous histiocytoma (MFH) has been gone. Most sarcomas called MFH were reclassified to be high-grade pleomorphic forms of leiomyosarcoma, liposarcoma, rhabdomyosarcoma, and other sarcomas by recent molecular technologies. However, about 10% to 15% of sarcomas called MFH before, still cannot be given a precise classification, and these are now called undifferentiated pleomorphic sarcoma or are still called MFH. Further molecular approaches including proteomic approaches are imperative to classify these unclassified sarcomas for improving clinical outcomes of the patients with soft tissue sarcomas. This article is part of a Special Issue entitled: Medical Proteomics.
KW - Classification
KW - MFH
KW - Proteomics
KW - STS
UR - http://www.scopus.com/inward/record.url?scp=84939954855&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939954855&partnerID=8YFLogxK
U2 - 10.1016/j.bbapap.2014.08.012
DO - 10.1016/j.bbapap.2014.08.012
M3 - Article
C2 - 25173742
AN - SCOPUS:84939954855
VL - 1854
SP - 696
EP - 701
JO - Biochimica et Biophysica Acta - Proteins and Proteomics
JF - Biochimica et Biophysica Acta - Proteins and Proteomics
SN - 1570-9639
IS - 6
ER -